| Literature DB >> 34698411 |
Adrian Beyde1, Alexa L Thomas1,2, Kristina M Colbenson3, Benjamin J Sandefur4, Imtithal Kisirwan4, Aidan F Mullan5, Shawn W O'Driscoll6, Ronna L Campbell4.
Abstract
OBJECTIVES: Many guidelines for septic olecranon bursitis recommend aspiration of the bursa prior to initiation of antimicrobial therapy despite the absence of robust clinical data to support this practice and known risk of aspiration complications. Our objective was to describe outcomes associated with empiric antibiotic therapy without bursal aspiration among emergency department (ED) patients with suspected septic olecranon bursitis.Entities:
Keywords: aspiration; emergency department; management; olecranon bursitis; septic bursitis
Mesh:
Substances:
Year: 2021 PMID: 34698411 PMCID: PMC8766900 DOI: 10.1111/acem.14406
Source DB: PubMed Journal: Acad Emerg Med ISSN: 1069-6563 Impact factor: 5.221
FIGURE 1Patient enrollment and outcomes.1One patient had both a subsequent bursal aspiration and subsequent hospitalization for parenteral antibiotics. MRSA, methicillin‐resistant Staphylococcus aureus; MSSA, methicillin‐sensitive Staphylococcus aureus
Olecranon bursitis patient and ED management based on ED bursal aspiration and ED disposition
| Characteristic | Patients, No. (%) | |||||
|---|---|---|---|---|---|---|
| ED bursal aspiration ( | Admitted ( | Dismissed with antibiotics ( | Dismissed without antibiotics ( | All patients ( |
| |
| Age (years), median (IQR) | 45 (39–52) | 54 (42–61) | 58 (45–70) | 59 (47–69) | 57 (42–69) | 0.583 |
| Sex | 0.041 | |||||
| Female | 0 (0) | 11 (28) | 21 (14) | 7 (9) | 39 (14.6) | |
| Male | 4 (100) | 28 (72) | 126 (86) | 69 (91) | 227 (85.3) | |
| Race | 0.503 | |||||
| White | 4 (100) | 35 (90) | 138 (94) | 69 (91) | 246 (92.8) | |
| Black | 0 (0) | 3 (8) | 3 (2) | 1 (1) | 7 (2.6) | |
| Asian | 0 (0) | 0 (0) | 1 (1) | 1 (1) | 2 (0.7) | |
| Other | 0 (0) | 1 (3) | 5 (3) | 5 (7) | 11 (4.1) | |
| ED presentation | ||||||
| Reported fever | 2 (50) | 9 (23) | 17 (12) | 0 (0) | 28 (10.4) | <0.001 |
| Fever in ED | 0 (0) | 2 (5) | 2 (1) | 0 (0) | 4 (1.5) | 0.144 |
| Erythema | 4 (100) | 39 (100) | 133 (91) | 28 (37) | 204 (77.0) | <0.001 |
| Cellulitis | 0 (0) | 17 (44) | 36 (24) | 4 (5) | 57 (21.4) | <0.001 |
| Warmth | 3 (75) | 30 (77) | 97 (66) | 19 (25) | 149 (56.0) | <0.001 |
| Swelling | 4 (100) | 37 (95) | 142 (97) | 67 (88) | 250 (94.0) | 0.070 |
| Abrasion/wound | 1 (25) | 9 (23) | 49 (33) | 7 (9) | 66 (24.8) | <0.001 |
| Tenderness | 3 (75) | 28 (72) | 100 (68) | 32 (42) | 163 (61.3) | 0.002 |
| Pain | 4 (100) | 36 (92) | 126 (86) | 59 (78) | 225 (84.6) | 0.159 |
| Comorbid conditions | ||||||
| Steroids | 1 (25) | 5 (13) | 22 (15) | 11 (14) | 39 (14.6) | 0.677 |
| HIV | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 1 (0.4) | >0.99 |
| Gout | 0 (0) | 4 (10) | 9 (6) | 9 (12) | 22 (8.2) | 0.420 |
| Arthritis | 0 (0) | 2 (5) | 2 (1) | 0 (0) | 4 (1.5) | 0.136 |
| History of MRSA | 0 (0) | 2 (5) | 4 (3) | 1 (1) | 7 (2.6) | 0.474 |
| Diabetes | 0 (0) | 7 (18) | 17 (12) | 13 (17) | 37 (13.8) | 0.502 |
| Other immunocompromised | 0 (0) | 3 (8) | 2 (1) | 1 (1) | 6 (2.2) | 0.172 |
| Imaging/laboratory values | ||||||
| Radiograph | 2 (50) | 31 (80) | 88 (60) | 40 (53) | 161 (60.5) | 0.030 |
| Ultrasound | 2 (50) | 2 (5) | 10 (7) | 1 (1) | 15 (5.6) | 0.007 |
| WBCs |
10 (9–11) [ |
10 (7–12) [ |
10 (8–12) [ |
9 (8–10) [ |
10 (8–12) [ | 0.739 |
| CRP |
— [ |
50 (22–89) [ |
32 (14–50) [ |
11 (5–61) [ |
36 (14–62) [ | 0.006 |
| ESR |
— [ |
19 (10–41) [ |
11 (6–24) [ |
12 (7–41) [ |
14 (7–31) [ | 0.112 |
| ED orthopedic consult | 0 (0) | 29 (74) | 36 (25) | 4 (5) | 69 (25.9) | <0.001 |
| Antibiotics prescribed at dismissal | 4 (100) | 32 (82) | 147 (100) | 0 (0) | 183 (68.8) | — |
| Cephalosporin (first/second generation) | 0 (0) | 10 (26) | 75 (51) | 0 (0) | 85 (32.0) | — |
| Cephalosporin (third generation) | 0 (0) | 4 (10) | 1 (1) | 0 (0) | 5 (1.9) | — |
| Penicillin | 2 (50) | 1 (3) | 21 (14) | 0 (0) | 23 (8.6) | — |
| Clindamycin | 1 (25) | 0 (0) | 11 (7) | 0 (0) | 12 (4.5) | — |
| Trimethoprim/sulfamethoxazole | 1 (25) | 5 (13) | 11 (7) | 0 (0) | 17 (6.4) | — |
| IV vancomycin | 0 (0) | 3 (8) | 2 (1) | 0 (0) | 5 (1.9) | — |
| Doxycycline | 0 (0) | 3 (8) | 6 (4) | 0 (0) | 9 (3.3) | — |
| Other | 0 (0) | 2 (5) | 4 (3) | 0 (0) | 7 (2.6) | — |
| Cephalosporin + trimethoprim/sulfamethoxazole | 0 (0) | 2 (5) | 10 (7) | 0 (0) | 12 (4.5) | — |
| Cephalosporin + doxycycline | 0 (0) | 1 (3) | 2 (1) | 0 (0) | 3 (1.1) | — |
| Penicillin + trimethoprim/sulfamethoxazole | 0 (0) | 1 (3) | 3 (2) | 0 (0) | 4 (1.5) | — |
| Penicillin + doxycycline | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 1 (0.4) | — |
| Inpatient antibiotics | ||||||
| Cephalosporin (first/second generation) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (0.4) | — |
| Trimethoprim/sulfamethoxazole | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (0.4) | — |
| Doxycycline | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (0.4) | — |
| IV cefazolin | 0 (0) | 6 (15) | 0 (0) | 0 (0) | 6 (2.3) | — |
| IV trimethoprim/sulfamethoxazole | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (0.4) | — |
| IV vancomycin | 0 (0) | 15 (38) | 0 (0) | 0 (0) | 15 (5.6) | — |
| Cephazolin + vancomycin | 0 (0) | 4 (10) | 0 (0) | 0 (0) | 4 (1.5) | — |
| Ceftriaxone + vancomycin | 0 (0) | 3 (8) | 0 (0) | 0 (0) | 3 (1.1) | — |
| Vancomycin + other | 0 (0) | 5 (13) | 0 (0) | 0 (0) | 5 (1.9) | — |
| Lost to follow‐up | 1 (25) | 1 (3) | 13 (9) | 9 (12) | 24 (9.0) | 0.174 |
| At least 6 months of follow‐up | 3 (75) | 34 (87) | 122 (83) | 61 (80) | 220 (82.7) | 0.792 |
| At least 3 months of follow‐up | 3 (75) | 34 (87) | 128 (87) | 64 (84) | 229 (86.1) | 0.851 |
Data are reported as n (%) unless otherwise specified. SI conversion factors: To convert WBC to 109/L multiply by 1. To convert CRP to mg/L multiply by 10.
Abbreviations: CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; HIV, human immunodeficiency virus; IQR, interquartile range; MRSA, methicillin‐resistant Staphylococcus aureus; WBC, white blood cell count.
Unless otherwise noted.
Medians and IQRs are given only for patients with available data, indicated for each entry.
Both patients were dismissed on IV daptomycin.
Two of the four patients were dismissed with MRSA coverage (one IV daptomycin, one minocycline).
p‐values are from comparisons between the four disposition groups given in the table using Kruskal‐Wallis tests for continuous features and chi‐square or Fisher's exact tests for categorical features.
Patient outcomes based on ED bursal aspiration and ED disposition among patients with olecranon bursitis for whom follow‐up was available
| Characteristic | Patients | |||||
|---|---|---|---|---|---|---|
| ED bursal aspiration ( | Admitted ( | Dismissed with antibiotics ( | Dismissed without antibiotics ( | All patients ( |
| |
| Uncomplicated resolution | 2 (66) | 34 (89) | 118 (88) | 61 (91) | 215 (88.8) | 0.496 |
| Subsequent interventions | ||||||
| Subsequent hospitalization | 1 (25) | 0 (0) | 9 (7) | 2 (3) | 12 (5.0) | 0.053 |
| Bursal surgery | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 1 (0.4) | — |
| Subsequent bursal aspiration | 0 (0) | 4 (10) | 8 (6) | 2 (3) | 14 (5.8) | 0.411 |
| Incision and drainage | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 1 (0.4) | 0.446 |
| Non‐ED aspiration provider | — | |||||
| Primary care | 0 (0) | 0 (0) | 3 (38) | 2 (100) | 5 (36) | |
| Rheumatology | 0 (0) | 0 (0) | 3 (38) | 0 (0) | 3 (21) | |
| Orthopedics | 0 (0) | 3 (75) | 0 (0) | 0 (0) | 3 (21) | |
| Other | 0 (0) | 1 (25) | 2 (25) | 0 (0) | 3 (21) | |
| Bursitis‐related subsequent visits | 2 (67) | 31 (82) | 79 (59) | 26 (39) | 139 (57.8) | 0.002 |
| Subsequent visits | ||||||
| Primary care | 1 (50) | 21 (66) | 49 (61) | 19 (73) | 90 (64.3) | |
| Rheumatology | 0 (0) | 0 (0) | 0 (0) | 1 (4) | 1 (0.7) | |
| Orthopedics | 0 (0) | 1 (3) | 3 (4) | 2 (8) | 6 (4.3) | |
| Infectious disease | 0 (0) | 6 (19) | 1 (1) | 0 (0) | 7 (5.0) | |
| ED | 1 (50) | 1 (3) | 23 (29) | 3 (12) | 28 (20) | |
| Other or multiple | 0 (0) | 2 (6) | 3 (4) | 1 (4) | 6 (4.3) | |
| Antibiotic complications | — | |||||
| Allergic reaction | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 1 (0.4) | |
| Anaphylaxis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
|
| 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Clinically significant diarrhea | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Data are reported as n (%).
Unless otherwise noted.
Includes both outpatient and inpatient aspirations. Percentages are given relative to the number of follow‐up aspirations.
Percentages are given relative to the number of patients with bursitis‐related subsequent visits.
p‐values are from comparisons between the four disposition groups given in the table using Fisher's exact tests for categorical features.